KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $235.0 million.

  • Sarepta Therapeutics' Net Income towards Common Stockholders fell 6744.28% to -$451.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$252.2 million, marking a year-over-year decrease of 626.07%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • According to the latest figures from FY2024, Sarepta Therapeutics' Net Income towards Common Stockholders is $235.0 million, which was up 143.83% from -$536.1 million recorded in FY2023.
  • Sarepta Therapeutics' 5-year Net Income towards Common Stockholders high stood at $235.0 million for FY2024, and its period low was -$704.1 million during FY2022.
  • In the last 3 years, Sarepta Therapeutics' Net Income towards Common Stockholders had a median value of -$536.1 million in 2023 and averaged -$335.1 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Net Income towards Common Stockholders tumbled by 68.13% in 2022, and later skyrocketed by 143.83% in 2024.
  • Sarepta Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$554.4 million in 2020, then rose by 24.46% to -$418.8 million in 2021, then slumped by 68.13% to -$704.1 million in 2022, then rose by 23.85% to -$536.1 million in 2023, then spiked by 143.83% to $235.0 million in 2024.